Next Phase Newsletter

A venture capital firm with offices in Canada was founded by a healthcare investment team that has a successful track record of identifying, building, and growing life science companies. The firm recently launched a $200M (CAD) fund, through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later-stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with like-minded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

With offices worldwide, a large medtech company invests in medical technology companies that are strategically relevant. The firm invests in new technologies via venture investing, collaborations, incubation, or M&A. The firm invests worldwide.

The firm’s primary focuses within healthcare include in-vitro diagnostics (particularly immuno and molecular diagnostics), digital lab services (including capacity management, care coordination, technologies that help physicians make diagnoses and other key decisions) and AI technologies in healthcare. The firm will invest in any medical indication area, and prefers companies that have at least attained proof of concept data or with a product on market demonstrating traction and revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A firm is focused on investing in early-stage companies with disruptive technologies and is actively seeking entrepreneurs with a track record of success. The firm’s primary focus includes robotics, biotechnology, hardware, artificial intelligence, blockchain, novel materials, and other advanced technologies. The firm invests in seed round and Series A round, the typical investment is between $100,000 and $500,000. The firm is supported by well-established Chinese partners. The firm strives to assist their portfolio companies in reaching a global market.

The firm’s primary focus includes robotics, biotechnology, hardware, artificial intelligence, blockchain, novel materials, and other advanced technologies.

The firm is looking for founders with strong academic credentials and sector expertise. The firm actively seek entrepreneurs with a track record of success.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

The VC is a human longevity-focused VC firm based in New York, USA. The firm invests in Pre-seed, Seed, Seed+ companies at $200K with a possible follow-on of $400K and Series A & B rounds at $800K with a

potential $1.6M follow-on. The firm will consider opportunities primarily in the Americas, UK, and EU. Also, the firm actively supports companies by providing connections to human capital providers, governmental entities, and suitable investors to help founders grow their business.

The firm will look at a broad spectrum of products and services within space technology and human longevity. The partners had previously invested in 20+ early-stage technology companies/ funds with active private deal-flow in the verticals of space, healthcare, and robotics. The firm is investing in biomarkers, diagnostics, digital health, and therapeutics (RX and OTC), dealing with the hallmarks of aging on the longevity side of things.

The firm will invest in privately held companies only and will participate as a co-investor. The firm prefers to invest in companies with at least three founders and will not invest in sole founder companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The fund is the corporate venture arm of an Australian-based company with an interest in infection prevention technology, primarily in the hospital setting. The firm is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products into the market. Within the area of infection prevention and control, the fund will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm will invest globally.

The firm has a focus on digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare acquired infection.

The fund will only make strategic investments that align with the corporate vision. The firm is an active investor, and will typically take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Japanese pharmaceutical company is dedicated to research, development, and commercialization of innovative products for unmet medical needs in the areas of musculoskeletal disorders, including pain management and critical care. The company is vastly investing to expand their presence from its domestic roots in Japan to become a Global Specialty Pharma. To achieve above goal, the company is looking for opportunities of early stage pipelines and/or research collaborations with global rights to expand their business worldwide.

The company Is pursuing attractive, new in-licensing and research collaboration opportunities in the following areas of interest: in relation to in-licensing opportunities in pre-clinical stage for the global market, the company is interested in chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, and muscle-related disorders (i.e. DMD, ALS, etc.) In relation to research collaboration opportunities for the global market, the company is interested in drug seeds for chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, as well as platform technologies related to drug delivery, formulation, excipients, oral, transdermal, nanoparticle, controlled release, and targeting.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm will seek global rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An investment firm based in the USA manages corporate venture funds of a large health system and  looks to invest in companies of strategic interest to its major health plan investors while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.